Zacks Investment Research
09 Jul 2026, 19:30 UTC · 10w ago
Verdict
Headline leans bullish. We score UTHR +1.00 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
United Therapeutics' TETON-1 phase III study for IPF achieved its primary endpoint with statistically significant improvement in lung function.
More positive than 99% of claims this week
The phase III ADVANCE OUTCOMES study for the PAH candidate ralinepag met both primary and secondary endpoints.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 92% of claims this week
United Therapeutics intends to submit a new drug application for ralinepag to the FDA in the second half of 2026.
More positive than 76% of claims this week
United Therapeutics' shares have gained 14% year-to-date, significantly outperforming its industry's 0.8% decline.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company has seen significant stock gains driven by major clinical breakthroughs and positive phase III data for Tyvaso and ralinepag.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
6h ago
−10.8%
Price is moving against the score
$494.63 vs $554.34 close before publication (Jul 8) · not market-adjusted
UTHR chart →
